The IPO Floodgates Open, Tariffs Tighten, and the Innovation Economy Braces for Its Biggest Test Yet

Three of the most consequential IPOs in history are queuing up at the same time. Semiconductor tariffs are redrawing supply chain maps. And the venture capital market just posted its most active quarter on record. Here is what the Silicon Valley ecosystem needs to know this week.

1. SpaceX Files Confidentially: The Starting Gun Has Been Fired

On April 1, SpaceX submitted a confidential draft S-1 registration statement to the SEC, confirming what capital markets practitioners have been anticipating for months. The company is targeting a June roadshow and a Nasdaq listing at a reported valuation of up to $1.75 trillion — which, if achieved, would make it the largest IPO in history, surpassing Saudi Aramco’s $29 billion debut in 2019 by a factor of nearly three.

The mechanics of the confidential filing process are worth understanding. Under the JOBS Act, emerging growth companies — and certain other qualified issuers — can submit draft registration statements to the SEC for review without immediate public disclosure. SpaceX will be required to make its prospectus public at least 15 days before its roadshow begins. That means investors, lawyers, and the market broadly should expect the formal S-1 to drop in late April or May, with the roadshow following shortly after. June 8 has been reported as a likely roadshow launch date.

A few legal and structural issues bear watching as the S-1 becomes public. First, governance: SpaceX’s February 2026 all-stock merger with Elon Musk’s xAI — which valued SpaceX at $1 trillion and xAI at $250 billion — will require careful accounting treatment and disclosure. The deal is unusual in that the acquired company was controlled by the same individual who controls the acquirer. Conflicts of interest, related-party transaction disclosures, and the adequacy of any fairness process will almost certainly be areas of SEC comment letter focus. Second, dual-class share structure: Musk has signaled he intends to retain operational control post-IPO. The governance rights and economic terms of any supervoting structure will be central to institutional investor analysis. Third, government contract concentration: SpaceX has received over $24 billion in federal contracts since 2008. Revenue dependence on a single government counterparty — particularly at a moment of significant federal budget scrutiny — is a material risk factor that the S-1 will need to address with care.

For GCs at companies considering IPOs in the current window, the SpaceX filing is both an inspiration and a complication. The oxygen it will consume in the investor relations ecosystem — the analyst attention, the roadshow bandwidth, the retail investor excitement — will be substantial. Timing your own offering relative to the SpaceX roadshow window matters, and anyone planning a public debut in the June-August window should be in close dialogue with their bankers about positioning.

2. The AI Mega-IPO Trio: $240 Billion Looking for a Home

SpaceX is not alone. Bloomberg’s April 1 report confirmed what the venture and capital markets community has been tracking: 2026 is shaping up as the year that SpaceX, OpenAI, and Anthropic all go public. The combined targeted raise across the three companies — approximately $75 billion for SpaceX, up to $60 billion for Anthropic, and potentially over $100 billion for OpenAI — exceeds the total capital raised in the U.S. IPO market across a full decade from 2016 to 2025.

The sequencing matters enormously. SpaceX is targeting June. Anthropic has reportedly set its sights on an October debut. OpenAI is eyeing Q4, though internal disagreements between the company’s CEO and CFO about timing remain unresolved. The concentration of these three listings in a narrow window has sparked genuine debate among market participants: will the SpaceX IPO energize broader risk appetite and open the window for others, or will the sheer scale of these offerings drain institutional liquidity and crowd out the mid-cap names that have been waiting for a more receptive market?

From a legal standpoint, OpenAI’s path to public markets remains the most structurally complex. The company recently completed a recapitalization that converted it from a nonprofit to a for-profit entity — a transformation that involved significant governance restructuring, charitable commitments, and the unwinding of a unique corporate form that had no real precedent in capital markets history. Anthropic, which hired Wilson Sonsini to begin IPO preparation, faces its own set of disclosure challenges: the company has delayed the launch of its most advanced AI model due to cybersecurity risk concerns, a decision that will require careful treatment in the risk factors section of any prospectus.

One structural dynamic that deserves attention: all three companies have acknowledged that standard institutional float percentages are unworkable at their scale. A 15% float on a $1.75 trillion company requires absorbing roughly $260 billion from public markets in a single transaction. As a result, the floats are expected to be unusually thin — likely in the 3–8% range — which creates its own set of governance and liquidity concerns for public shareholders from day one.

3. Semiconductor Tariffs: The Legal and Commercial Implications for the Innovation Stack

Underneath the IPO excitement, a slower-moving but equally consequential story is reshaping the legal and commercial landscape for Silicon Valley companies: semiconductor tariffs.

In January 2026, the U.S. government finalized a 25% tariff on select high-end semiconductor imports — specifically targeting the advanced AI chips that underpin the modern digital economy. The proclamation, signed on January 14, follows a nine-month national security investigation and marks a significant escalation from the more targeted Section 301 tariffs that preceded it. The current structure is layered and deliberately complex: heightened reciprocal tariffs are suspended through November 10, 2026, a new Section 301 framework sets current rates at 0% with a scheduled increase on June 23, 2027, and earlier tariffs may still apply depending on product classification and country of origin.

For GCs and their companies, the legal and operational implications run in several directions. Contract review is the most immediate: any agreement that prices hardware components without explicit tariff pass-through provisions, or that specifies delivery timelines without accounting for supply chain disruption risk, deserves a fresh look. Material adverse change and force majeure clause analysis is warranted where tariff-driven cost increases materially alter the economics of existing commercial arrangements.

On the disclosure side, public companies with meaningful semiconductor procurement should be assessing whether tariff exposure is material enough to require explicit risk factor disclosure or MD&A discussion in upcoming SEC filings. The SEC has been attentive to trade policy risk disclosure since the first round of Section 301 tariffs, and the January 2026 escalation is a triggering event for that analysis.

Longer term, the geopolitical trajectory is toward further regionalization of the semiconductor supply chain. The January 2026 U.S.-Taiwan trade agreement, under which Taiwanese chipmakers committed to at least $250 billion in U.S. fab investment in exchange for reduced tariff rates, accelerates the domestic manufacturing buildout that was already underway under the CHIPS Act. TSMC’s Arizona fabs, Samsung’s Texas expansion, and the broader ecosystem of packaging, materials, and equipment companies receiving CHIPS Act awards are all part of a deliberate industrial policy that will reshape procurement maps over the next five to ten years. Companies that get ahead of this transition — in their supply chain documentation, their customer and vendor contracts, and their M&A strategy — will be better positioned than those that treat current tariff structures as temporary noise.

4. Venture Capital: A Record Quarter and What It Means

Q1 2026 was the largest single quarter for global venture capital in history. Crunchbase data shows investors deployed approximately $300 billion into roughly 6,000 startups worldwide — up more than 150% both quarter-over-quarter and year-over-year. Approximately 80% of that capital flowed into AI-related sectors, a dramatic concentration compared to the roughly 50% AI share for the full year of 2025.

Several specific transactions stand out for their legal and structural significance. Anysphere, the company behind the Cursor coding tool, raised a $2.3 billion Series D at a $29.3 billion valuation — nearly tripling its value in five months on the back of $1 billion in annualized revenue and 100x year-over-year growth. Legora, an AI legal platform, closed a $550 million Series D at a $5.55 billion valuation with a cap table that includes virtually every major Silicon Valley venture firm. Nexthop AI raised $500 million in Series B funding from Lightspeed and Andreessen Horowitz to build switching infrastructure for AI data centers.

The concentration of capital into AI infrastructure and applications raises a legal issue that GCs and their boards should be attuned to: at what point does an AI-era startup’s valuation become so disconnected from current revenue and a credible path to profitability that the risk disclosures in a subsequent financing or public offering become inadequate? The SEC has long scrutinized the adequacy of risk factor disclosure in high-growth, high-valuation technology companies. The de-SPAC era taught us what happens when optimistic projections meet public market scrutiny. The AI investment cycle has its own version of that reckoning coming — and the companies and counsel that prepare their disclosure infrastructure now will be better positioned when it arrives.

Looking Ahead

The next 90 days will be among the most consequential in recent Silicon Valley history. The SpaceX S-1 will drop and will be the most widely read prospectus in a generation. The tariff window for semiconductors will narrow as scheduled rate increases approach. And the venture capital market will continue to test the proposition that AI companies can absorb virtually unlimited capital at ever-increasing valuations.

For GCs at public and pre-public companies, the practical agenda is clear: review your material contracts for tariff exposure and pricing risk, assess your disclosure obligations in light of AI-related risks and market developments, and make sure your governance infrastructure is ready for the scrutiny that public market life demands. The complexity of this environment is an argument for engagement, not delay.

Louis Lehot is a partner at Foley & Lardner LLP, where he advises entrepreneurs, investors, and public companies on capital markets transactions, M&A, and venture financings. He can be reached at llehot@foley.com. This briefing is for informational purposes only and does not constitute legal advice. Attorney advertising — prior results do not guarantee a similar outcome. Opinions expressed here are my own and not my firm.